

Board Meeting in Public

Tuesday, 20 May 2025

Title of Paper	Safeguarding and Prevent: Management of the Vulnerable and at-risk Policy (BLP4/1)	Agenda No.	4.1
Nature of Paper	<input checked="" type="checkbox"/> Official	<input type="checkbox"/> Official Sensitive	
Author(s)	Natalie Hawker, National Safeguarding Lead		
Lead Executive	Dee Thiruchelvum, Chief Nursing Officer		
Non-Executive Director Sponsor	-		
Presenter(s) at Meeting	Dee Thiruchelvum, Chief Nursing Officer		
Presented for	<input checked="" type="checkbox"/> Approval <input type="checkbox"/> Information* <input type="checkbox"/> Assurance <input type="checkbox"/> Update		
Executive Summary (max 300 word count)			
<p>BLP4/1 Safeguarding and Prevent: Management of the Vulnerable and At-Risk policy has been reviewed and updated with further comments and updating following the policy presentation at Clinical Governance Committee (April 2025). The refinements are inclusive of updated individual roles and accountabilities and governance group titles.</p> <p>MPD961/7 Safeguarding and Prevent has been updated to reflect current safeguarding practice across NHSBT and has been aligned to wider policies within the organisation and national practice standards. This MPD compliments BLP4/1 and has been re-formatted to support ease of reading and understanding. The term “vulnerable adult” has been updated to “an adult at risk” or “an adult with care and support needs”. Specific guidance on children and adults at risk who are waiting at blood and blood component donation sessions, allegations management, and workplace misconduct is now included. Appendices have been added to demonstrate processes for managing a safeguarding concern and allegations against staff. This ensures as an organisation we are meeting our statutory function for Safeguarding.</p>			
Previously Considered by			
Safeguarding Oversight Group; Clinical Quality and Safety Governance group (Approved September 2024); Clinical Governance Group (April 2025, changes as detailed above)			
Recommendation	BLP4/1 is considered fit for purpose and the Board is asked to confirm approval of this Board Level Policy. MPD961/7 is being shared in the Meeting Review Room for information only.		
Risk(s) identified (Link to Board Assurance Framework Risks)			
Risk CCG-03 Safeguarding (residual score 8 : 4 (impact) x2 (likelihood). The updated MPD961/7 will support and lower the risk management particularly with regards to allegations management.			
Strategic Objective(s) this paper relates to: [Click on all that apply]			
<input type="checkbox"/> Collaborate with partners <input checked="" type="checkbox"/> Invest in people and culture <input type="checkbox"/> Drive innovation <input type="checkbox"/> Modernise our operations <input type="checkbox"/> Grow and diversify our donor base			
Appendices:	<ul style="list-style-type: none"> • BLP4/1 • MPD961/7 can be found in the Review Room for Meeting 		